Literature DB >> 32170946

Endoscopic and Histological Assessment, Correlation, and Relapse in Clinically Quiescent Ulcerative Colitis (MARQUEE).

Mark T Osterman1, Frank I Scott2, Franz F Fogt1, Erin D Gilroy1, Susan Parrott1, Joseph Galanko3, Raymond Cross4, Alan Moss5, Hans H Herfarth3, Peter D R Higgins6.   

Abstract

OBJECTIVE: It is difficult to predict relapse in quiescent ulcerative colitis (UC), but newer endoscopic and histological indices could improve this. This study aimed to determine in UC patients in clinical remission (1) the prevalence of active endoscopic and histological disease; (2) the correlation between endoscopic and histological scores; and (3) the predictive power of these scores for clinical relapse.
DESIGN: This multicenter prospective cohort study conducted by the Crohn's and Colitis Foundation Clinical Research Alliance included 100 adults with UC in clinical remission undergoing surveillance colonoscopy for dysplasia. Endoscopic activity was assessed using the Mayo endoscopic score (MES), ulcerative colitis endoscopic index of severity (UCEIS), and ulcerative colitis colonoscopic index of severity (UCCIS). Histology was assessed with the Riley index subcomponents, total Riley score, and basal plasmacytosis.
RESULTS: Only 5% of patients had an MES of 0, whereas 38% had a score of 2 to 3; using the UCEIS, the majority of patients had at least mild activity, and 15% had more severe activity. Many patients also had evidence of histological disease activity. The correlations among endoscopic indices, histological subcomponents, and total score were low; the highest correlations occurred with the subcomponent architectural irregularity (ρ = 0.43-0.44), total Riley score (ρ = 0.35-0.37), and basal plasmacytosis (ρ = 0.35-0.36). Nineteen patients relapsed clinically over 1 year, with the subcomponent architectural irregularity being the most predictive factor (P = 0.0076).
CONCLUSIONS: This multicenter prospective study found a high prevalence of both endoscopic and histological disease activity in clinically quiescent UC. The correlations between endoscopy and histology were low, and the power to predict clinical relapse was moderate.
© 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  endoscopic index; histological index; mucosal healing

Mesh:

Year:  2021        PMID: 32170946     DOI: 10.1093/ibd/izaa048

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  4 in total

1.  A Novel Method for Quantifying Intestinal Inflammatory Burden in Inflammatory Bowel Disease Using Register Data.

Authors:  Jordan E Axelrad; Michael C Sachs; Jonas F Ludvigsson; Ola Olén
Journal:  Clin Epidemiol       Date:  2020-10-09       Impact factor: 4.790

2.  Further research on the clinical relevance of the ulcerative colitis colonoscopic index of severity for predicting 5-year relapse.

Authors:  Natsuki Ishida; Shunya Onoue; Takahiro Miyazu; Satoshi Tamura; Shinya Tani; Mihoko Yamade; Moriya Iwaizumi; Yasushi Hamaya; Satoshi Osawa; Takahisa Furuta; Ken Sugimoto
Journal:  Int J Colorectal Dis       Date:  2021-08-18       Impact factor: 2.571

3.  Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis.

Authors:  Angelo Viscido; Marco Valvano; Gianpiero Stefanelli; Annalisa Capannolo; Chiara Castellini; Eugenia Onori; Antonio Ciccone; Filippo Vernia; Giovanni Latella
Journal:  BMC Gastroenterol       Date:  2022-03-03       Impact factor: 3.067

4.  Advanced technology for assessment of endoscopic and histological activity in ulcerative colitis: a systematic review and meta-analysis.

Authors:  Olga Maria Nardone; Yifat Snir; James Hodson; Rosanna Cannatelli; Nunzia Labarile; Keith Siau; Cesare Hassan; Henit Yanai; Iris Dotan; Subrata Ghosh; Marietta Iacucci
Journal:  Therap Adv Gastroenterol       Date:  2022-04-29       Impact factor: 4.802

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.